Brief: Maat Pharma Reports Cash Position, Receives FDA Response Letter On MaaT013

Maat Pharma SA

03/02/2023 06:37

Feb 3 (Reuters) - Maat Pharma SA  MAAT.PA :
    * MAAT PHARMA RECEIVES U.S. FDA RESPONSE OUTLINING PATH
FORWARD
FOR INVESTIGATIONAL NEW DRUG APPLICATION FOR MAAT013 IN PATIENTS
WITH ACUTE GRAFT-VERSUS-HOST DISEASE AND REPORTS CASH AND
REVENUES FOR FOURTH QUARTER 2022
    * AS OF DECEMBER 31, 2022, TOTAL CASH AND CASH EQUIVALENTS
WERE
EUR 35.2 MILLION
    * MAAT PHARMA REPORTED GROSS REVENUES OF EUR 0.6 MILLION FOR
QUARTER ENDED DECEMBER 31, 2022
    * FDA LETTER INDICATES THAT AGENCY AGREES TO A DEFINED LIST
OF
CONDITIONS THAT COULD ENABLE CLINICAL EVALUATION OF MAAT013 IN
U.S
    * COMPANY WILL PROMPTLY PREPARE A COMPLETE RESPONSE LETTER
AND IN
INTERIM, CLINICAL HOLD REMAINS

Source text for Eikon:  ID:nBw72Cf7qa 
Further company coverage:  MAAT.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))